Clinical Trials Logo

Pulmonary Embolism clinical trials

View clinical trials related to Pulmonary Embolism.

Filter by:

NCT ID: NCT06051032 Recruiting - Clinical trials for Pulmonary Embolism and Thrombosis

Compative Study of PE in Thrombosed AVF After Balloon Thrombectomy vs. Thromboaspiration.

Start date: July 21, 2023
Phase: N/A
Study type: Interventional

The goal of this multicentric clinical trial is to compare the incidence of pulmonary thromboembolism (PTE), assessed through AngioCT, in the endovascular treatment of acute thrombosis in native and prosthetic arteriovenous fistulas (AVF). The main questions it aims to answer are: - What is the difference in the incidence of pulmonary thromboembolism (PTE) assessed by AngioCT in endovascular treatment of acute thrombosis of native and prosthetic arteriovenous fistulas using balloon thrombectomy versus thromboaspiration systems? - What is the primary patency rate of arteriovenous fistulas treated with balloon thrombectomy versus thromboaspiration systems? - What is the clinical success rate in the treatment of arteriovenous fistulas using balloon thrombectomy compared to thromboaspiration systems? - What are the costs associated with the different thrombectomy techniques in the treatment of arteriovenous fistulas? Participants will be underwent to balloon thrombectomy versus thromboaspiration systems. Researchers will compare the patients treated with balloon thrombectomy and thromboaspiration systems to see if the incidence of PE is comparable and to evaluate the primary and secondary patency rates of both thrombectomy techniques, the clinical technical success rate, and the costs associated with each technique.

NCT ID: NCT06043726 Recruiting - Pulmonary Embolism Clinical Trials

Diagnostic Accuracy of Arterial-alveolar Oxygen Gradient in Low Risk Patients With Suspected Pulmonary Embolism

DAGPE
Start date: September 1, 2022
Phase:
Study type: Observational

Introduction: The diagnosis of pulmonary embolism (PE) is a challenge in the Emergency Department. D-dimer based diagnostic algorithms for PE have a very high sensitivity, but rely upon a vast amount of CT angiography and potentially unnecessary exposure to radiation. An accurate diagnostic algorithm that does not involve d-dimer testing might reduce this burden. An abnormal Alveolar-arterial oxygen gradient (A-a gradient) seems to increase the chance of PE. However, a normal A-a gradient on its own does not exclude the diagnosis. In this paper, the accuracy of A-a gradient testing and a combination of Years criteria with A-a gradient testing will be assessed. Methods: This is a prospective, single center, observational study. All patients that present at our emergency department from September 2022 until September 2023 with a suspicion of pulmonary embolism will be analyzed for eligibility and included in the study after informed consent. The aim is to include at least 230 patients in the study. Analysis: The primary outcome is the diagnostic accuracy of a YEARS and A-a gradient based algorithm for pulmonary embolism. The secondary outcome is the potential decrease in performed imaging in order to exclude pulmonary embolism. Valorisation An accurate A-a gradient-based algorithm for pulmonary embolism in low risk patients will be a step towards an improved clinical risk score. We aim to reduce the amount of diagnostic imaging, i.e. CT-angiography. Meaning less, potentially unnecessary, exposure to radiation for the patient. Furthermore, it could lower healthcare costs by reducing expensive diagnostic imaging.

NCT ID: NCT06041594 Not yet recruiting - Pulmonary Embolism Clinical Trials

Treating Pulmonary Embolism With Laguna Thrombectomy System (TRUST)

TRUST
Start date: May 2024
Phase: N/A
Study type: Interventional

This is a prospective, multi-center, pivotal study to demonstrate the safety and effectiveness of the Laguna Thrombectomy System for the treatment of pulmonary embolism. The Laguna Thrombectomy System is an investigational device which consists of the Laguna Clot Retrieverâ„¢ System and the Malibu Aspiration Catheterâ„¢ System. These devices are manufactured by Innova Vascular, Inc.

NCT ID: NCT06038630 Recruiting - Anemia Clinical Trials

129Xe MRI Cardiopulmonary

Start date: January 12, 2024
Phase: Phase 2
Study type: Interventional

The goal of this NIH-sponsored study is to characterize three biomarkers derived from 129Xe gas exchange MRI and to understand how they change in response to interventions.

NCT ID: NCT06037096 Recruiting - Pulmonary Embolism Clinical Trials

Implementation of a Structured Post-pulmonary Embolism Follow-up Model

Start date: March 15, 2022
Phase: N/A
Study type: Interventional

Venous thromboembolism (VTE), clinically presenting as deep vein thrombosis or pulmonary embolism (PE) is the third most common cardiovascular disease and is associated with substantial short- and long-term morbidity and mortality and high costs of care. In addition negative physical and mental complications following VTE are common. However in terms of PE, there are no structured follow-up programs in Denmark and there is considerable variation in practice patterns of post-PE management both within and between countries. The Attend-PE project aims to develop, test and implement a structured follow-up model in a hospital setting for patients with pulmonary embolism. The Attend-PE is a pre-post intervention study and will estimate the effectiveness of implementing the structured care model on a national level.

NCT ID: NCT06017271 Not yet recruiting - Lung Cancer Clinical Trials

Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer

Start date: September 30, 2023
Phase:
Study type: Observational

The occurrence and progression of lung cancer is related to visceral adipose tissue (VAT). Epicardial adipose tissue (EAT) is a kind of VAT, producing a variety of inflammatory cytokines and adipokines, participating in the formation of local inflammation, promoting the formation of pre-thrombotic state, and leading to the occurrence of thromboembolism. Patients with lung cancer have increased inflammatory response and are more prone to suffer thrombosis. However, in lung cancer patients, the clinical correlation between EAT and pulmonary embolism has not been reported. Objective: To analyze the risk factors of poor prognosis in lung cancer patients with PE, and to explore the predictive value of EAT in pulmonary embolism events and death in lung cancer patients. Methods: EAT volume and density, as well as anthropometric and blood biomarkers, were evaluated in a sample of lung cancer patients, half with pulmonary embolism and half without. The incidence of adverse prognosis and related factors were followed up by telephone.

NCT ID: NCT06015529 Recruiting - Pulmonary Embolism Clinical Trials

Diagnostic Strategy for Suspected Pulmonary Embolism Based on 4PEPS

SPEED&PEPS
Start date: November 29, 2023
Phase: N/A
Study type: Interventional

The increased use of diagnostic imaging and especially computed tomography pulmonary angiography in patients suspected of pulmonary embolism (PE) is an important point of concerns. The goal of this pragmatic cluster-randomized trial is to compare the diagnostic strategy based on the four-level pulmonary embolism probability score (4PEPS) and current practices. The main questions it aims to answer is: "Does the diagnostic strategy based on 4PEPS significantly reduce the use of thoracic imaging without increasing the risk of serious adverse events as compared to current diagnostic practices?" Patients suspected of having PE in the participating emergency departments will be included and followed for 90 days. In ten centers, the emergency physicians will apply the 4PEPS strategy and in ten other centers, the emergency physicians will be free to do as they see fit. Researchers will compare the two groups of patients to see if the rate of diagnostic thoracic imaging tests and the rate of adverse events related to diagnostic strategies will differ.

NCT ID: NCT06009484 Completed - Colon Cancer Clinical Trials

VTE Incidence After Curative Colon Cancer Surgery in an ERAS Program

Start date: January 1, 2014
Phase:
Study type: Observational [Patient Registry]

Based on data on a cohort of 2,141 patients undergoing elective colonic cancer resection in an ERAS program, the incidence of postoperative thromboembolic events is estimated in patients no receiving prolonged thromboembolic prophylaxis.

NCT ID: NCT05992168 Not yet recruiting - Clinical trials for PE - Pulmonary Thromboembolism

Stent-Retriever for Acute Massive Pulmonary Embolism (SRAME)

SRAME
Start date: December 15, 2023
Phase: N/A
Study type: Interventional

To evaluate treatment outcomes of patients diagnosed with pulmonary embolism.

NCT ID: NCT05946811 Withdrawn - Pulmonary Embolism Clinical Trials

Macitentan to Prevent PRVO

MAC-PRO
Start date: May 1, 2024
Phase: Phase 3
Study type: Interventional

About half of patients who suffer of a pulmonary embolism (blood clots in the lungs), do not clear completely the clots overtime, increasing the risk of having a new blood clot in the lungs and elevated blood pressure in the pulmonary artery; therefore, developing fatigue, shortness of breath, and heart failure. The objective of this clinical trial is to compare 3 months of daily Macitentan (a medicine to increase the diameter of the pulmonary artery) in addition to blood thinners vs. blood thinners alone in patients with acute blood clots in the pulmonary artery: Question 1: Whether the use of Macitentan in addition to blood thinners enhances the process of cleaning the blood clot in the pulmonary artery compared to blood thinners alone. Question 2: Whether the use of Macitentan in addition to blood thinners is associated to improve the fatigue and shortness of breath in patients after a pulmonary embolism compared to blood thinners alone. Participants will be asked to take a capsule for 3 months in addition to blood thinners. The capsule could contain either Macitentan (medicine) or a placebo (not medicine). In 3 months, participants will have a new image of the pulmonary artery to document the cleaning of the clots. Also, blood and urine samples will be collected, as well as a questionnaire will be filled out. In 6 months, patients will have repeated images of the heart as well as repeated questionnaires.